Data Assets

Global Hub for High-Fidelity Data in R&D and AI Training

We provide exclusive access to one of the deepest and most dynamically evolving biomedical databases in Europe. Our core asset is not just a collection of static snapshots, but continuous multi-year health trajectories spanning up to 12 years of follow-up. We specialize in delivering ML-ready datasets that include deep single-cell sequencing (scRNA-seq), granular clinical phenotypes, and rare patient cohorts, significantly accelerating the target validation cycle for pharmaceutical and biotech R&D teams.

Data access is managed through a rigorous multi-stage transparency and security protocol. Upon request, our team conducts a comprehensive Feasibility Study to confirm the availability of specific biomarkers, depth of annotation, and cohort alignment with your research objectives. All operations are conducted under international protocol SOP 00.2 and strictly comply with the EU AI Act and GDPR, ensuring the highest level of ethical integrity and legal protection for your future patents and clinical developments.

Key Features of Our Database:

• 12-Year Longitudinality: Unique time-series data for modeling disease progression over a decade.

• Deep Multi-omics: High-fidelity scRNA-seq and AI-extracted pathology features.

• Compliance & Ethics: Fully certified by the Ethics Committee (Austria) and aligned with the latest EU regulations for AI and data governance.

• Exclusive Cohorts: Access to rare samples (SCLC, Longevity 92+) and data from cutting-edge treatment protocols (e.g., Tarlatamab).

• Agile Feasibility: Rapid availability checks and customized dataset preparation tailored to your specific inquiry.